Devices Surgery Oncology

 News Release - January 30, 2006

Intraop Medical Receives Third Mobetron Order from Italy

Seven Systems Now Used in Europe for Cancer Treatment

SUNNYVALE, Calif.--(HSMN NewsFeed)--Jan. 30, 2006--Intraop Medical Corporation (OTCBB: IOPM ) received its third order from Italy for a Mobetron, the Company's proprietary system for intraoperative radiation therapy (IORT). The order to be delivered later this month is from the Azienda Ospedaliera S. Croce e Carle, the largest public hospital in the Western Piemonte region of Italy, serving approximately 3 million people.

Fulvio Moirano, General Director, and Riccardo Bedogni, Managing Director, reported that the hospital had received a donation to purchase the Mobetron from the Foundation "Fondazione Cassa di Risparmio di Cuneo." "We are very pleased to receive a donation from the Foundation," they stated. "After several months of study by our specialists, the Foundation accepted the results of our analysis that the best approach to cancer treatment was to implement an IORT program at our hospital. Their donation allowed us to purchase the Mobetron."

"The hospital made a careful evaluation of its options, and concluded that the Mobetron was the best choice for its IORT program," said Ernesto Lanzotti, President of MD51, and Intraop Medical's partner for IORT in Italy.

Dr. Giuseppe Marchetti, Director of the Cuneo Hospital Radiotherapy Department, said: "Last year alone we treated almost 1,300 new cancer patients in our department. We plan to use the Mobetron for pancreatic cancer, sarcomas, colorectal cancer and urological cancers, in addition to early stage breast cancer."

Don Goer, Ph.D., President and CEO of Intraop, responded: "Italy has long been known throughout Europe as an early adopter of new technology, so it is gratifying to see our base of installed Mobetrons in Italy continue to grow. We are especially pleased that the Mobetron was selected by Ospedaliera S. Croce e Carle to start their IORT program, and are hopeful that additional hospitals in Italy will add IORT and the Mobetron to their cancer treatment programs."

The Mobetron is a portable device weighing 2,800 lbs. that can be used in virtually any operating room. The system, which delivers radiation therapy at the time of surgery, when residual tumor cells are most active, is the only portable device designed specifically for IORT treatment of various forms of cancer.

About Azienda Ospedaliera S. Croce e Carle

The Hospital Azienda Ospedaliera S. Croce e Carle is the largest public hospital in the Western Piemonte region of Italy. Located in the city of Cuneo, in the foothills of the Italian Alps, it serves a population base of approximately 3 million people. The hospital currently treats over 2,000 cancer patients using surgery, chemotherapy and radiation therapy.

About Intraop Medical Corporation

Intraop Medical Corporation improves the quality of life for cancer patients through the development, manufacturing and sales of its proprietary Mobetron system. The Mobetron is a mobile electron-beam system designed for intraoperative radiation therapy (IORT) treatment of cancer, coronary/vascular restenosis and other medical applications. IORT is the direct application of radiation to a tumor while a patient is undergoing cancer surgery. Intraop Medical Corporation has revolutionized this procedure by developing the first mobile device for delivering IORT in the operating room without the necessity of adding extensive radiation shielding. The Mobetron is easily transportable between operating rooms and/or hospitals, further increasing system usage. The system is FDA-approved for sale in the United States and has received the equivalent foreign approvals: CE Mark in Europe, JIS in Japan and SDA in China. Intraop Medical Corporation is based in Sunnyvale, California. For more information on Intraop Medical Corporation please visit www.intraopmedical.com.

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Source: Intraop Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.